Cholesterol Metabolites Analysis in Human Thyroid and Iodine Resistance (OXYTHYR)

Institut Claudius Regaud

Status: Completed

Conditions: Thyroid Cancer

Treatments: Other: Metabolites dosage

Study type: Observational

Funder types: Other

Identifiers

NCT04821336

21HLVADS01

Details and patient eligibility

About

The study team previously shown that a cholesterol metabolite, dendrogenin A (DDA) differentiates anaplastic thyroid cancer cell lines and that its mRNA expression is diminished in human radioiodine refractory thyroid cancer samples. The team aim to quantify via mass spectrometry and immunohistochemistry DDA and other cholesterol metabolites in thyroid cancer versus healthy thyroid tissue human samples.

Full description

Retrospective study to analyze tissue samples of patients after thyroid surgery at Claudius Regaud Institute Toulouse, France, for thyroid cancer or thyroid aggressive lymphoma or benign thyroid pathology or other head&neck pathology necessitating total thyroidectomy despite normal thyroid.

Analysis focused on cholesterol metabolites quatification by mass spectrometry in liquid and gas phase.

Enrollment: 30 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have undergone surgery at Institut Claudius Regaud for thyroid or laryngeal cancer confirmed by histology.
• Patients who have consented before surgery, for the use of participants samples for future researches.

Exclusion criteria

• None

Trial design

30 participants in 1 patient group

Thyroid tissue samples

Description:

from 30 patients, tissue samples , frozen and embedded paraffin have been collected and preserved for research. For this study, tumoral tissue and healthy tissue will be used;

Treatment:

Other: Metabolites dosage